Apolipoprotein B Secretion Assay from Primary Hepatocytes

Materials and reagents

1. 25 mg/mL IV collagenase (Sigma-Aldrich, catalog number: C5138)

2. DMEM culture medium (Gibco, catalog number: 8123306)

3. Penicillin-Streptomycin solution (P/S), 100× (Caisson, catalog number: PSL01)

4. Phosphate buffered saline (PBS) (Meilunbio, catalog number: MA0015)

5. Fetal bovine serum (FBS) (Vistech, catalog number: SE100-011)

6. Acetone (TGREAG, catalog number: 105003)

7. APOB polyclonal antibody (Proteintech, catalog number: 20578-1-AP)

8. ALBUMIN monoclonal antibody (Proteintech, catalog number: 66051-1-Ig)

9. Glucose (HARVEYBIO, catalog number: SR1742)

10. NaHCO₃ (TGREAG, catalog number: 114005)

11. NaCl (TGREAG, catalog number: 112008)

12. HEPES (Sigma, catalog number: V900477)

13. KCl (Sinopharm Chemical Reagent Co., Ltd, catalog number: 10016328)

14. KH₂PO₄ (Sinopharm Chemical Reagent Co., Ltd, catalog number: 10017628)

15. MgSO₄·7H₂O (Sinopharm Chemical Reagent Co., Ltd, catalog number: 10013018)

16. Tris-HCl (Sigma, catalog number: V900483)

17. Nonidet P-40 (Sigma, catalog number: 56741)

18. Glycerol (Sigma, catalog number: G7893)

19. EGTA (Sigma, catalog number: 03777)

20. CaCl₂ (TGREAG, catalog number: 104034)

1. Krebs Ringer with glucose (KRG) buffer (see Recipes)

2. Solution C (see Recipes)

3. Buffer 1 (see Recipes)

4. Buffer 2 (see Recipes)

5. Lysis buffer (see Recipes)

Recipes

1. KRG buffer (1 L)

   Note: KRG buffer (pH = 7.4) should be prepared immediately before use. Filter through a 0.22 μm membrane before use.

   Reagent	Final concentration	Quantity or Volume
   Glucose	20 mM	3.6 g
   NaHCO3	25 mM	2.0 g
   NaCl	120 mM	7.0 g
   HEPES	1 M (pH 7.45)	5 mL
   Solution C (Recipe 2)	N/A	10 mL
   Total	N/A	Set volume to 1 L with ddH2O




2. Solution C (1 L)

   Reagent	Final concentration	Quantity or Volume
   KCl	480 mM	35.79 g
   KH2PO4	120 mM	16.33 g
   MgSO4·7H2O	120 mM	29.58 g
   Total	N/A	Set volume to 1 L with ddH2O




3. Buffer 1

   Add 100 μL of 50 mM EGTA to 50 mL of KRG buffer.




4. Buffer 2

   Add 100 μL of 1 M CaCl₂ and 25 mg of IV collagenase to 50 mL of KRG buffer.




5. Lysis buffer

   Note: Store at 4 °C and add protease inhibitor before use.

   Reagent	Final concentration
   Tris-HCl (pH 7.4)	50 mM
   Nonidet P-40	1%
   Glycerol	10%
   NaCl	150 mM

Laboratory supplies

1. Cell strainer (Falcon, catalog number: 352350)

2. Millex-GP Filter, 0.22 μm, PES 33 mm, non-sterile (Millex, catalog number: SLGP033NS)

3. Axygen MaxyClear Snaplock microtubes (Axygen, catalog number: MCT-150-C)

4. 10 cm cell culture dish (JET, catalog number: TCD010100)

5. 6-well cell culture dish (JET, catalog number: TCP010006)

6. 50 mL centrifuge tube (JET, catalog number: CFT011500)

7. 10 mL pipettes (JET, catalog number: GSP010010)

8. Perfusion set (BD Intima II, catalog number: 383405; TNTC-1066)

9. Eye scissors (Beijing Hongbai Technology Co., Ltd., catalog number: 2101157)

10. Forceps (Beijing Hongbai Technology Co., Ltd., catalog number: HC10704)

11. Nitrocellulose membrane (DiNing, catalog number: 66485)

Equipment

1. Centrifuge (Eppendorf, model: 5424R)

2. Centrifuge (Eppendorf, model: 5810)

3. GE Amersham Imager600 (GE Healthcare, catalog number: 29083463)

4. Western blot equipment (Bio-Rad, catalog number: 1658033)

Procedure

1. Isolation and culture of primary mouse hepatocytes

   1. Sterilize eye scissors and forceps.

   2. Preheat two 50 mL solutions of KRG buffer in a 37 °C water bath for 30 min.

   3. Using preheated KRG buffer, prepare buffer 1 and buffer 2 (see Recipes).

   4. Weigh and anesthetize the mice used for experiments by intraperitoneal injection of tribromoethanol according to the local animal handling protocols.

   5. After complete anesthesia, fix the mouse on a clean foam board, spray with 75% alcohol, and wipe with sterile gauze.

   6. Cut the abdominal wall, separate the subcutaneous tissue, and detach the abdominal skin on both sides with a needle. Open the abdominal cavity; the liver, portal vein, hepatic artery, and hepatic vein are exposed.

   7. Prepare an infusion set. Insert the venous indwelling needle into the vena cava, open the infusion valve, cut the portal vein, and perfuse the liver at a rate of 2 mL/min using Buffer 1 to remove residual blood.

   8. Add 25 mg of IV collagenase to buffer 2 close to the time of use.

   9. After the blood is thoroughly washed out, switch to buffer 2 for liver digestion. The collagenase perfusion process lasts approximately 1–2 min.

   10. When the liver becomes enlarged, white, and loose (such that pressing lightly leaves a small dent), place the liver into a 10 cm dish with the remaining buffer 2 (approximately 15 mL) and transfer to a biosafety cabinet for further processing.

   11. After collagenase perfusion, the liver becomes loose and soft and can be easily cut up with a pair of 10 cm eye scissors. Cut the liver into small pieces in a culture dish. Pipette the digested liver tissue until dispersed with a 10 mL pipette. Filter the mixture through a 70 μm cell strainer into a 50 mL centrifuge tube to remove tissue debris.

   12. Add pre-chilled DMEM to the tube for cell resuspension

   13. Centrifuge at 50× g for 4 min at 4 °C, discard the supernatant.

   14. Repeat steps A12–A13 three times until the supernatant is clear. Perform all washing steps with DMEM.

   15. Discard the supernatant, add prewarmed complete medium (DMEM with 10% FBS and 1% P/S), and seed the cells in a culture dish according to the desired cell density for subsequent experiments. Recommended cell density: 4 × 10⁵ cells per well of a 6-well dish.

   16. It usually takes 3–4 h for cell adhesion and before the cells can be used for follow-up experiments.




2. Lipoprotein secretion detection in primary mouse hepatocytes

   1. Change the medium to FBS-free DMEM preheated at 37 °C (other treatments can be performed simultaneously according to experimental requirements): 10 mL for a 10 cm dish and 2 mL per well of a 6-well dish.

   2. Collect the medium after 4–8 h depending on the specific experimental conditions.

   3. Centrifuge at 15,000× g for 15 min at 4 °C to remove cell debris.

   4. Transfer the supernatant to a new centrifuge tube, add four times the sample volume of pre-chilled acetone, mix well, and precipitate at -20 °C overnight or at -80 °C for 2 h.

   5. After centrifugation at 15,000× g for 10 min at 4 °C, resuspend the pellet using lysis buffer and perform western blotting.

      Note: The conditions for western blot can be as follows: Run the gel on a 3%–8% tris-acetate gel at 100 V. When the 250 kDa marker reaches the middle, typically after 75 min, transfer to a nitrocellulose membrane overnight at 200 mA by using fresh transfer buffer. The primary antibodies used for overnight incubation were APOB polyclonal antibody and ALBUMIN monoclonal antibody.

   6. The results of analyzing APOB and albumin in the culture medium by immunoblotting are shown in Figure 1.

      
      

      
      Figure 1. Decreased apolipoprotein B (APOB) secretion after Mn²⁺ treatment. Primary hepatocytes from wild-type mice were treated with 125 μM MnCl₂ for 8 h. APOB and albumin in the medium were analyzed by immunoblotting.

Validation of protocol

This protocol or parts of it has been used and validated in the following research article: Wang et al. [12]. Manganese regulation of COPII condensation controls circulating lipid homeostasis. Nature Cell Biology (Figure 1, panel d; Figure 5, panel a).

Acknowledgments

The work is supported by the National Natural Science Foundation of China (NSFC: 32100947 to X.W., 32125021, 92254308, 91957119, 91954001, 31571213 to X.W.C) and the National Key R&D Program (2021YFA0804802). This protocol has been used in Nature Cell Biology [12].

Competing interests

All authors declare no conflict of interest.

Ethical considerations

All animal housing and use were approved by the Institutional Animal Care and Use Committees of Peking University, an AAALAC-accredited laboratory animal.

References

1. Roth, G. A., Abate, D., Abate, K. H., Abay, S. M., Abbafati, C., Abbasi, N., Abbastabar, H., Abd-Allah, F., Abdela, J., Abdelalim, A., et al. (2018). Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392(10159): 1736–1788.
2. Goldstein, J. L. and Brown, M. S. (2015). A Century of Cholesterol and Coronaries: From Plaques to Genes to Statins. Cell 161(1): 161–172.
3. Bentzon, J. F., Otsuka, F., Virmani, R. and Falk, E. (2014). Mechanisms of Plaque Formation and Rupture. Circ. Res. 114(12): 1852–1866.
4. Fisher, E. A. and Ginsberg, H. N. (2002). Complexity in the Secretory Pathway: The Assembly and Secretion of Apolipoprotein B-containing Lipoproteins. J. Biol. Chem. 277(20): 17377–17380.
5. Ference, B. A., Kastelein, J. J. P. and Catapano, A. L. (2020). Lipids and Lipoproteins in 2020. JAMA 324(6): 595.
6. Mehta, A. and Shapiro, M. D. (2021). Apolipoproteins in vascular biology and atherosclerotic disease. Nat. Rev. Cardiol. 19(3): 168–179.
7. Ginsberg, H. N., Le, N. A., Goldberg, I. J., Gibson, J. C., Rubinstein, A., Wang-Iverson, P., Norum, R. and Brown, W. V. (1986). Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J. Clin. Invest. 78(5): 1287–1295.
8. Björkegren, J. L. and Lusis, A. J. (2022). Atherosclerosis: Recent developments. Cell 185(10): 1630–1645.
9. Bhatia, H. S., Becker, R. C., Leibundgut, G., Patel, M., Lacaze, P., Tonkin, A., Narula, J. and Tsimikas, S. (2023). Lipoprotein(a), platelet function and cardiovascular disease. Nat. Rev. Cardiol. e1038/s41569-023-00947-2.
10. Tsimikas, S. and Witztum, J. L. (2023). Oxidized phospholipids in cardiovascular disease. Nat. Rev. Cardiol. 21(3): 170–191.
11. Willeit, P., Ridker, P. M., Nestel, P. J., Simes, J., Tonkin, A. M., Pedersen, T. R., Schwartz, G. G., Olsson, A. G., Colhoun, H. M., Kronenberg, F., et al. (2018). Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. Lancet 392(10155): 1311–1320.
12. Wang, X., Huang, R., Wang, Y., Zhou, W., Hu, Y., Yao, Y., Cheng, K., Li, X., Xu, B., Zhang, J., et al. (2023). Manganese regulation of COPII condensation controls circulating lipid homeostasis. Nat. Cell Biol. 25(11): 1650–1663.